Evaluation of the Benefits for Overall Health Following Cochlear Implant Treatment in the Elderly Population
Cochlear Implant and Healthy Aging: A Multinational, Multicentre Observational Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Paris, France
- Groupe Hospitalier de La Pitié Salpétrière
-
Toulouse, France
- ENT Department-Hôpital Purpan
-
-
-
-
-
Haifa, Israel
- Bnai Zion Medical Center
-
Petah Tikva, Israel
- Rabin Medical Center (Beilinson)
-
-
-
-
-
Padova, Italy
- ENT Otosurgery Department-Azienda Ospedaliera di Padova
-
Piacenza, Italy
- ENT Department Ospedale Guglielmo da Saliceto
-
-
-
-
-
Las Palmas de Gran Canaria, Spain
- Complejo Hospitalario Universitario Insular Materno Infantil
-
Pamplona, Spain
- Clinica Universitaria de Navarra
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Unilateral CI candidates with bilateral post-lingual deafness with intention to treat
- ≥ 60 years at first unilateral cochlear implant
- Implant ear: meets all local criteria for cochlear implant treatment
- Contralateral ear: average pure tone thresholds indicate a moderately-severe to profound hearing loss (4 freq. average: 0.5, 1, 2 and 3 or 4 kHz > 56 dBHL).
- Willingness to participate in and to comply with all study procedures
- Fluency in languages used to assess clinical performance
- Appropriate expectations from routine cochlear implant treatment
- Able to decide on study participation personally and independently sign their consent
Exclusion Criteria:
- Significantly/severely dependent or fragile
- Unable to provide consent personally
- Unable to complete questionnaires for self-assessment independently
- Unilateral hearing loss
- Sequential and simultaneous bilateral cochlear implant recipients
- Ossification or other cochlear anomalies preventing full electrode insertion
- Retro cochlear or central origins of hearing impairment.
- Significant comorbidities preventing study participation (e.g. blindness, immobility or in a wheel chair, severe aphasia)
- Medical contraindications to surgery
- Clinic Standard fail criteria for cochlear implant candidacy in regards to chronic depression, dementia, and cognitive disorders.
- Unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedure and prosthetic device.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Commercial Nucleus Cochlear Implant Systems
|
Commercially available Nucleus Cochlear Implant Systems, including Data Logging functionality
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Health Related Quality of Life Following Cochlear Implant Treatment
Time Frame: pre-implant surgery, 12 months post-surgery
|
Assessed via the Health Utilities Index Mark III (HUI 3) questionnaire.
HUI-3 classification system consists of 8 attributes including vision, hearing, speech, ambulation, dexterity, emotion, cognition, and pain.
HUI-3 values range from -0.36 to 1.00.
A health utility value of 1.00 indicates perfect health while a score of 0.00 indicates death.
The change in scores is presented.
A positive value indicates an improved quality of life, a negative value indicates impaired quality of life.
|
pre-implant surgery, 12 months post-surgery
|
|
Change in Health Related Quality of Life Following Cochlear Implant Treatment
Time Frame: pre-implant surgery, 18 months post-surgery
|
Assessed via the Health Utilities Index Mark III (HUI 3) questionnaire.
HUI-3 classification system consists of 8 attributes including vision, hearing, speech, ambulation, dexterity, emotion, cognition, and pain.
HUI-3 values range from -0.36 to 1.00.
A health utility value of 1.00 indicates perfect health while a score of 0.00 indicates death.
The change in scores will be presented.
A positive value indicates an improved quality of life, a negative value indicates impaired quality of life.
|
pre-implant surgery, 18 months post-surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bart Volckaerts, PhD, Cochlear
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CEL5671
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.